Production methods for rabies vaccine

Journal of Industrial Microbiology and Biotechnology

Volumn 18, Issue 5, 1997, Pages 340-347

  Perez O ^a   Paolazzi, C C ^a  

^a Instituto Nacional de Microbiologia Dr Carlos GMalbran   (Argentina)

Author keywords

Production methods; Rabies vaccines

Indexed keywords

RABIES VACCINE;

ANIMAL CELL; BIOREACTOR; CELL CULTURE; CELL DENSITY; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MANUFACTURE; NERVOUS TISSUE; NONHUMAN; REVIEW; TECHNIQUE; VIRUS STRAIN;

ANIMALS; BRAIN; CELL LINE; EMBRYO; HUMANS; RABIES; RABIES VACCINES; RABIES VIRUS;

ANIMALIA;

EID: 0030813574     PISSN: 13675435     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jim.2900391     Document Type: Review

References (128)

1. Abelseth MK. 1964. An attenuated rabies vaccine for domestic animals produced in tissue culture. Can Vet J 5: 279-281.
2. Abelseth MK. 1967. Further studies on the use of ERA rabies vaccine in domestic animals. Can Vet J 8: 221-227.
3. Abelseth MK. 1964. Propagation of rabies virus in pig kidney cell culture. Can Vet J 5: 84-87.
4. Atanasiu P, H Tsiang and A Gamet. 1974. Nouveau vaccin antirabique humain de culture cellulaire primaire. Ann Microbiol (Inst Pasteur) 125B: 419-432.
5. Atanasiu P, H Tsiang, M Lavergne and J Chermann. 1977. Purification par centrifugation zonale d'un vaccin antirabique humain obtenu sur cellules rénales de foetus bovins. Ann Microbiol (Inst Pasteur) 128B: 297-302.
6. Atanasiu P, H Tsiang, P Reculard, F Aguilon, M Lavergne and P Adamovicz. 1978. Zonal centrifuge purification of human rabies vaccine obtained on bovine fetal kidney cells: biological results. Dev Biol Stand 40: 35-44.
7. Bachmann G, R Steffen, R Gluck, A Wegmann and M Schar. 1985. Pre-exposure rabies vaccination using a new duck embryo vaccine. Schweiz Med Wochenschr 115: 863-865.
8. Bahmanyar M. 1974. Results of antibody profiles in man vaccinated with the HDCS vaccine with various schedules. Symp Ser Immuno-biol Stand 21: 231-239.
9. Bahmanyar M, A Fayaz, S Nour-Salehi, M Mahammadi and H Koprowski. 1976. Successful protection of humans exposed to rabies infection postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. J Am Med Assoc 236: 2751-2754.
10. Barth R and O Jaeger. 1970. Unterschungen mit einegen Tollwutvirusstämmen in verschiedenen Gewebkultursystemen. Zentralblatt für Veterinärmedizin 17: 363-380.
11. Barth R, H Gruschkau, U Bijok, J Hilfenhaus, J Hinz, L Milcke, H Moser, O Jaeger, H Ronneberger and E Weinmann. 1984. A new inactivated tissue culture rabies vaccine for use in man: evaluation of PCEC-vaccine by laboratory test. J Biol Stand 12: 29-46.
12. Barth R, O Gruschkau, O Jaeger and L Milcke. 1981. Concentration of rabies antigen and potency test. In: Cell Culture Rabies Vaccines and their Protective Effect in Man (Kuwert EK, TJ Wiktor and H Koprowski, eds), p 60, Proceedings of WHO Consultations, Essen, Federal Republic of Germany. International Green Cross, Geneva.
13. Bektimirova M, E Pille, K Matevosyan and F Nagieva. 1983. Rabies vaccine prepared from the virus grown in Japanese quail embryo cell cultures. Acta Virol 27: 59-64.
14. Berlin B, J Mitchell, G Burgoyne, D Oleson, W Brown, C Goswick and N McCullough. 1982. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine. J Am Med Assoc 247: 1726-1728.
15. Bijok U. 1985. Purified chick embryo cell (PCEC) rabies vaccine: a review of clinical development 1982-1984. In: Improvements in Rabies Postexposure Treatment (Vodopija I, KG Nicholson, S Smerdel and U Bijok, eds), p 103, Zagreb Institute of Public Health.
16. Biocca E and L Bellani. 1988. Oral vaccination in the control of feral rabies. Parasitologia 30: 3-12.
17. Burgoyne GH, KD Kajiya, DW Brown and JR Mitchell. 1985. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine using FRhL-2 cells. J Infect Dis 152: 204-210.
18. Cabrera J, DE Griffin and RJ Johnson. 1987. Unusual features of the Guillain-Barré syndrome after rabies vaccine prepared in suckling mouse brain. J Neurol Sci 81: 239-245.
19. Ciuchini F and C Buonavoglia. 1988. The Italian experience in the control of rabies III. Laboratory studies on SAD-B19 vaccine used in the fox vaccination campaign. Parasitologia 30: 35-47.
20. Crick J and F Brown. 1970. Efficacy of rabies vaccine prepared from virus grown in duck embryo. Lancet 1: 1106-1107.
21. Diamond L. 1967. Two spontaneously transformed cell lines derived from the same hamster embryo culture. Int J Cancer 2: 143-152.
22. Diaz AM, N Dellepiane and LF Palomo. 1989. Antirabies vaccine from the brain of the suckling rat: antigen composition and immunogenic capacity. Bol Ofic Sanit Panam 107: 185-195.
23. Dreesen DW, DB Fishbein, DT Kemp and J Brown. 1989. Two year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine forpre-exposure immunization. Vaccine 7: 397-400.
24. El Karamany RM. 1987. Production in Vero cells of an inactivated rabies vaccine from strain FRV/K for animal and human use. Acta Virol (Prague) 31: 321-328.
25. Erbolato EB, EV da Silva, O Miguel, P Sureau and PM Germano. 1989. The efficacy of the ERA rabies vaccine in mice against 4 antigenic variants of rabies virus. Rev Saude Publica 23: 447-454.
26. Farrar WE Jr, AR Warner Jr and S Vivona. 1964. Pre-exposure immunisation against rabies using duck embryo vaccine. Military Med 1: 960-965.
27. Fenje P. 1960. A rabies vaccine from hamster kidney tissue cultures: preparation and evaluation in animals. Can J Microbiol 6: 605-609.
28. Fenje P and L Pinteric. 1966. Potentiation of tissue culture rabies vaccine by adjuvants. Am J Pub Hlth 56: 2106-2113.
29. Fermi C. 1908. Über die Immunisierung Gegen Wutkrankheit. Zeitschrift für Hygiene und Infektionskrankheit 58: 233-276.
30. Follmann EH, DG Ritter and GM Baer. 1988. Immunization of arctic foxes (Alopex lagopus) with oral rabies vaccine. J Wildl Dis 24: 477-483.
31. Fournier P, B Montagnon, J Vincent-Falquet, N Ajjan, J Drucker and M Roumiantzeff. 1985. A new vaccine produced from rabies virus cultivated on Vero cells. In: Improvements in Rabies Postexposure Treatment (Vodopija I, KG Nicholson, S Smerdel and U Bijok, eds), p 115, Zagreb Institute of Public Health.
32. Fuenzalida E and R Palacios. 1955. Rabies vaccine prepared from the brains of infected suckling mice. Bol Inst Bact Chile 8: 3-10.
33. Gispen R, GJP Schmittman and B Saathof. 1965. Rabies vaccine derived from suckling rabbit brain. Arch Gesamte Virusforsch 15: 366-376.
34. Greenberg M and J Childress. 1960. Vaccination against rabies with duck embryo and Semple vaccines. J Am Med Assoc 173: 333-337.
35. Guesry P, P Sureau, L Lery, Y Cerisier, A Gamet and P Atanasiu. 1981. Comparative clinical trial of three different rabies vaccines used in pre-exposure vaccination. In: Cell Culture Rabies Vaccines and Their Protective Effect in Man (Kuwert E, TJ Wiktor and H Koprowski, eds), p 314, International Green Cross, Geneva.
36. Held JR and H López Adaros. 1971. Complicaciones neurológicas posteriores a la administración de vacuna antirrábica de cerebro de ratón lactante. Bol Ofic Sanit Panam 71: 50-59.
37. Hemachudha T, P Phanuphak, RT Johnson, DE Griffin, J Ratanavongsiri and W Siriprasomsup. 1987. Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies. Neurology 37: 550-556.
38. Hempt A. 1925. Sur une méthode rapide ole traitement antirabique. Ann Institut Pasteur 39: 632-640.
39. Hoskins JM. 1973. Duck-embryo vaccine. In: Laboratory Techniques in Rabies (Kaplan MM and H Koprowski, eds), p 243, Third Edition, WHO, Geneva, Monograph Series No. 23.
40. Javier RS, T Kunishita, F Koike and T Tabira. 1989. Semple rabies vaccine: presence of myelin basic protein and proteolipid protein and its activity in experimental allergic encephalomyelitis. J Neurol Sci 93: 221-230.
41. Johnson S, E Pearson and W Ing. 1985. Clinical responses in humans to rabies vaccine prepared in MRC-5 diploid cells from Canadian seed virus. In: Rabies in the Tropics (Kuwert E, C Mérieux, H Koprowski and K Bögel, eds), p 99, Springer-Verlag, Berlin-Heidelberg-New York-Tokyo.
42. Kabat EA, A Wolf and AE Bezer. 1948. Studies on acute disseminated encephalomyelitis produced experimentally in Rhesus monkeys. J Exp Med 88: 417-425.
43. Kaplan MM and H Koprowski. 1973. In: Laboratory Techniques in Rabies, Third Edition (Kaplan MM and H Koprowski, eds), WHO, Geneva, Monograph Series No. 23.
44. Kaplan MM, TJ Wiktor, RF Maes, JB Campbell and H Koprowski. 1967. Effect of polyions on the infectivity of rabies virus in tissue culture: construction of a single cycle growth curve. J Virol 1: 145-151.
45. Karakujumcan MK, BM Pariz and VD Solov'ev. 1973. Suckling rat brain vaccine. In: Laboratory Techniques in Rabies (Kaplan MM and H Koprowski, eds), p 213, Third Edition, WHO, Geneva, Monograph Series No. 23.
46. Kissling RE. 1958. Growth of rabies virus in non-nervous tissue cultures. Proc Soc Exp Biol Med 98: 223-225.
47. Kitala PM, KJ Lindquist, E Koimett, BK Johnson, CN Chunge, P Perrin and O Olsvik. 1990. Comparison of human immune responses to purified Vero cell and human diploid cell rabies vaccines by using two different antibody titration methods. J Clin Microbiol 28: 1847-1850.
48. Klietmann W, B Klietmann, J Cox and C Charbonnier. 1988. Effectiveness and tolerance of pre- and postexposure treatment with purified inactivated rabies vaccine prepared on Vero cell line. Vaccine 6: 39-43.
49. Kondo A, Y Takashima and M Suzuki. 1974. Inactivated rabies vaccine of chick embryo cell culture origin. Sym Ser Immunobiol Stand 21: 182-189.
50. Koprowski H. 1973. Chicken-embryo vaccine. In: Laboratory Techniques in Rabies (Kaplan MM and H Koprowski, eds), p 235, Third Edition, WHO, Geneva, Monograph Series No. 23.
51. Koutchoukali MA, J Blancou, G Chappuis, G Tixier, M Eloit, JP Ganiere, J Chantal, S Simon, A Berthier and B Toma. 1985. Serological response of the dog after primary antirabies vaccination using adjuvant or non-adjuvant vaccines. Ann Rech Vet 16: 345-349.
52. Kuwert E. 1967. Versuche zur Antigenität SchutzKraft und Encephalitogenität der Hempt vaccine sowie Betrachtungen zur Tollwutschutzimpfung. Deutschland Arch Hyg (Berlin) 151: 130-145.
53. Kuwert E, I Marcus, O Thraenhart and H Standacher. 1972. Prä-und postinfektionelle Tollwutschutzimpfung. Ausbildung neutralizierender Antikörper nach Applikation verschiedener Dosen einer Entenei-Vakzine beim Menschen. Deutsch Med Wochens 97: 1893-1898.
54. Kuwert E, TJ Wiktor and H Koprowski. 1980. In: Cell Culture Rabies Vaccines and Their Protective Effect in Man (Kuwert E, TJ Wiktor and H Koprowski, eds), Proc WHO Consultation Essen, Germany.
55. Larghi OP, VM Varela Díaz, E Soto, B Imas, A Cuba Caparó and E Fuenzalida. 1976. Laboratory investigations on neuroparalytic accidents associated with SMB rabies vaccine. III. Preservation of vaccine potency after elimination of murine brain myelin centrifugation. Ann Microbiol (Inst Pasteur) 12B: 567-572.
56. Larghi OP and AE Nebel. 1985. Duration of immunity afforded to cattle by a binary-ethylenimine inactivated rabies vaccine. Zbl Vet Med 32B: 609-615.
57. Larghi OP and AE Nebel. 1980. Rabies virus inactivation by binary ethylenimine: new method for inactivated vaccine production. J Clin Microb 11: 120-122.
58. Larghi OP, VL Savy, AE Nebel and A Rodnguez. 1976. Ethylenimine-inactivated rabies vaccine of tissue culture origin. J Clin Microbiol 3: 26-33.
59. Larghi OP, VL Savy, AE Nebel and A Rodriguez. 1979. Vacuna antirrábica inactivada con etilénimina. Duración de immunidad en perros. Revista Argentina de Microbiología 11: 102-107.
60. Lawson KF, H Chiu, M Matson, P Bachmann and JB Campbell. 1992. Studies on efficacy and stability of a vaccine bait containing ERA strain of rabies virus propagated in a BHK-21 cell line. Can J Vet Res 56: 135-141.
61. Lawson KF, R Hertler, KM Charlton, JB Campbell and AJ Rhodes. 1989. Safety and immunogenicity of ERA strain of rabies virus propagated m a BHK-21 cell line. Can J Vet Res 53: 438-444.
62. Lépine P. 1973. Fermi-type vaccine. In: Laboratory Techniques in Rabies (Kaplan MM and H Koprowski, eds), p 199, Third Edition, WHO, Geneva, Monograph Series No. 23.
63. Lin F-T, X-Z Lu, S-B Cheng, G-F Wang, F-Z Zeng, L-M Lu, N-M Cheng and J-Z Fang. 1985. Further study on the stability and efficacy of the primary hamster kidney cell rabies vaccine. In: Improvements in Rabies Postexposure Treatment (Vodopija I, KJ Nicholson, S Smerdel and U Bijok, eds), p 37, Zagreb Institute of Public Health.
64. Lin F-T, F-Z Zeng, L-M Lu, X-Z Lu, R-F Zeng, Y Yu and N-M Chang. 1983. The primary hamster kidney cell rabies vaccine: adaptation of viral strain, production of vaccine, and pre- and postexposure treatment. J Infect Dis 147: 467-473.
65. Lin FT. 1990. The protective effect of the large-scale use of PHKC rabies vaccine in humans in China. Bull World Health Organ 68: 449-454.
66. Linzenmeier G and E Kuwert. 1970. Encephalitogenität der Hempte-Vakzine beim Menschen. Neurologische Komplikationen nach Tollwutschutzimpfung in der Bundesrepublic von 1955 bis 1968. Zentralblatt für Bakteriologic Parasitekunde Infektionsbrankheiten und Hygiene, Abt original supplement 3: 102-117.
67. Lumbiganon P, P Chaiprasithikul, T Sookpranee, S Paholpak and C Wasi. 1989. Pre-exposure vaccination with purified chick embryo cell rabies vaccines in children. Asian Pac J Allergy Immunol 7: 99-101.
68. MacPherson I and M Stocker. 1962. Polyoma transformation of hamster cell clones. An investigation of genetic factors affecting cell competence. Virology 16: 147-151.
69. McFarlane JO and CG Culbertson. 1954. Attempted production of allergic encephalomyelitis with duck embryo suspensions and vaccines. Can J Pub Health 45: 28-29.
70. Mendoca R and C Pereira. 1993. BHK cell growth on microcarriers in a bioreactor. Bol Tecnol 4: 13-16.
71. Montagnon BJ. 1989. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 70: 27-47.
72. Montagnon B, P Fournier and J Vincent-Falquet. 1985. Un nouveau vaccin antirabique a usage humain. In: Rabies in the Tropics (Kuwert E, C Mérieux, H Koprowski and K Bögel, eds), p 138, Springer-Verlag, Berlin-Heidelberg-New York-Tokyo.
73. Montagnon B, B Fanget and A Nicolas. 1981. The large-scale cultivation of Vero cells in microcarrier culture for virus vaccine production: preliminary results for killed poliovirus vaccine. Dev Biol Stand 47: 55-64.
74. Morgeaux S, N Tordo, C Gontier and P Perrin. 1993. Betapropiolactone treatment impairs the biological activity of residual DNA from BHK-21 cells infected with rabies virus. Vaccine 11: 82-88.
75. Pasteur L. 1885. Méthode pour prévenir la rage après morsure. Compt Rend Acad Sciences 101: 765-774.
76. Pasteur L. 1886. Sur les résultats de l'application de la méthode de prophylaxie de la rage. Bull Acad Médicine 15: 664-665.
77. Petermann HG, R Lang, R Branche, JP Soulebot and C Mackowiak. 1967. Réalisation d'un nouveau vaccin rabique a partir de culture cellulaire. C R Acad Sci (Paris) Ser D 265: 2143-2144.
78. Petermann HG, JP Soulebot, R Lang and R Branche. 1970. La saponine, adjuvant d'immunité pour la vaccination des bovins contre la rage. C R Acad Sci (Paris) 270: 234-236.
79. Plotkin SA and HF Clarke. 1971. Prevention of rabies in man. J Infect Dis 123: 227-240.
80. Plotz J and R Reagan. 1942. Science 95: 102.
81. Powell HM and CG Culbertson. 1950. Cultivation of fixed rabies virus in embryonated duck eggs. Public Health Reports (Washington) 65: 400-401.
82. Precausta P. 1974. Vaccin antirabique inactivé a usage vétérinaire préparé á partir de culture cellulaire. Symp Series Immunobiol Standard 21: 162-178.
83. Pretz AA, MJ Fernandes, Y Hayashi, P Germano and SP Burer. 1991. Preparation of rabies vaccine PV/BHK in oily emulsion and evaluation of immunogenic power in bovines. Arq Biol Tecnol 34: 609-616.
84. Roumiantzeff M, B Montagnon, J Vincent-Falquet, L Bussy and C Charbonnier. 1985. Rapport sur l'utilisation du vaccin rabique préparé sur culture de cellules diploides humaines pour l'immunisation avant et après exposition. In: Rabies in the Tropics (Kuwert E, C Mérieux, H Koprowski and K Bögel, eds), p 91, Springer-Verlag, Berlin-Heidelberg-New York-Tokyo.
85. Roumiantzeff M, N Ajjan, B Montagnon and JC Vincent-Falquet. 1985. Rabies vaccine produced in cell culture. Ann Inst Pasteur/Virol 136E: 413-424.
86. Rubin RH, MA Hattwick, S Jones, MB Gregg and VD Schwartz. 1973. Adverse reactions to duck embryo and rabies vaccine. Range and incidence. Ann Int Med 78: 643-649.
87. Sanjay L and E Papoustsakis. 1992. Agitation induced cell injury in microcarriers cultures. Protective effect of viscosity is agitation intensity dependent experiments and modeling. Biotechnol Bioengin 39: 95-107.
88. Sanders M, I Kiem and D Langunoff. 1953. AMA Arch Path 56: 148.
89. Scheiermann N, J Baer, J Hilfenhaus, I Marcus and G Zoulek. 1987. Reactogenicity and immunogenicity of the newly developed purified chick embryo cell (PCEC) - rabies vaccine in man. Zentralbl Bakteriol Mikrobiol Hyg [A] 265: 439-450.
90. Segre L. 1984. Antirabies vaccine for human use from suckling rat brain (letter). Medicina (Buenos Aires) 44: 220-221.
91. Seligman B Jr. 1973. Semple-type vaccine. In: Laboratory Techniques in Rabies (Kaplan MM and H Koprowski, eds), p 192, Third Edition, WHO, Geneva, Monograph Series No. 23.
92. Selimov MA and TA Aksenova. 1966. Tissue culture antirabic vaccine for human use. Symp Ser Immunobiol Stand 1: 377-380.
93. Selimov MA, TA Aksenova, L Gribencha, E Kljueva, M Guliev, S Mirozoeva, V Kocofane, N Anina-Radcenko, A Markkarjan, I Stepanova, A Kuznecova, N Presnecova, S Andreeva, A Fursova and E Soluba. 1974. Live and inactivated tissue culture rabies vaccine made from strain Vnukovo-32. Symp Ser Immunobiol Stand 21: 179-184.
94. Selimov MA, TA Aksenova, E Kljueva, L Gribencha and Y Lebedeva. 1978. Evaluation of the inactivated tissue culture rabies vaccine from the Vnukovo-32 strain. Results of its industrial production and field use for postexposure immunization of man. Dev Biol Stand 40: 57-62.
95. Selimov MA and VM Morogova. 1973. Phenolized, freezedried sheep brain vaccine. In: Laboratory Techniques in Rabies (Kaplan MM and H Koprowski, eds), pp 201-204, Third Edition, WHO, Geneva, Monograph Series No. 23.
96. Selvakumar R and TJ John. 1989. Immune response to purified chick embryo cell culture rabies vaccine (Rabipur) in dog-bite victims. Ind J Med Res 89: 217-220.
97. Semple D. 1911. The preparation of a safe and efficient antirabic vaccine. In: Scientific Memoires of the Officers of the Medical and Sanitary Departments of India, No. 144, New Series, Calcutta.
98. Sikes R. 1969. Rabies vaccines. Arch Environ Health 19: 862-867.
99. Smith AH. 1966. Prophylactic immunisation against rabies with duck embryo rabies vaccine. South African Med J 40: 1125.
100. Steck F, A Wandeler, P Bichsel, S Capt and L Schneider. 1982. Oral immunisation of foxes against rabies. A field study. L Zbt Vet Med 29B: 372-396.
101. Steck F, A Wandeler, P Bichsel, S Capt, R Haflinger and L Schneider. 1982. Oral immunisation of foxes against rabies. Laboratory and field studies. Comp Immun Microbiol Infect Dis 5: 165-171.
102. Stoel G. 1930. CR Soc Biol (Paris) 104: 851.
103. Sureau P, P Rollin, B Fritzell, C Loucq, F Marie, A Courrier, Ph Simonnet, J Arbogast, J Fremont, C Gaudiot and J Malo. 1985. Reactogenicity and immunogenicity of primary fetal bovine kidney cells (FBKC) rabies vaccine: postexposure treatment. In: Improvements in Rabies Postexposure Treatment (Vodopija I, KG Nicholson, S Smerdel and U Bijok, eds), p 47, Zagreb Institute of Public Health.
104. Svet-Molkavskij GL et al. 1965. An allergen-free antirabies vaccine. Bull WHO 32: 47-58.
105. Svjetlicic M, I Vodopija, S Smerdel, M Ljibicic, Z Baklaic, J Vincent-Falquet, X Pouradier-Duteil and M Zayet-Bechelet. 1985. Compatibility and immunogenicity of Merieux's purified Vero rabies vaccine (PVRV) in healthy subjects. In: Improvements in Rabies Postexposure Treatment (Vodopija I, KG Nicholson, S Smerdel and U Bijok, eds), p 123, Zagreb Institute of Public Health.
106. Swaddiwuthipong W, N Prayoonwiwat, P Kunasol and P Choomkasien. 1987. A high incidence of neurological complications following Semple anti-rabies vaccine. Southeast Asian J Trop Med Public Health 18: 526-531.
107. Swaddiwuthipong W, BG Weniger, S Wattanasri and MJ Warrell. 1988. A high rate of neurological complications following Semple anti-rabies vaccine. Trans R Soc Trop Med Hyg 82: 472-475.
108. Tierkel ES and RJ Sikes. 1967. Pre-exposure prophylaxis against rabies. Comparison of regimens. J Am Med Assoc 201: 911-914.
109. Tolson ND, KM Charlton, KF Lawson, JB Campbell and RB Stewart. 1988. Studies of ERA/BHK-21 rabies vaccine in skunks and mice. Can J Vet Res 52: 58-62.
110. Toro G, I Vergara and G Román. 1977. Neuroparalytic accidents of antirabies vaccination with suckling mouse brain vaccine. Arch Neurol 34: 694-700.
111. Turner GS. 1984. Manual for the production of rabies vaccine in Vero cell cultures. WHO. BLG/RA/84.1 Rev.1.
112. Ubol S, T Hemachudha, JN Whitaker and DE Griffin. 1990. Antibody to peptides of human myelin basic protein in post-rabies vaccine encephalomyelitis sera. J Neuroimmunol 26: 107-111.
113. Van Steenis G, AL Van Wezel, A Hannik, P Van der Marel, A Osterhaus, I de Grott, C Koning, J Lelyveld and E Ruitenberg. 1985. Immunogenicity of dog kidney cell rabies vaccine (DKCV). In: Rabies in the Tropics (Kuwert E, C Mérieux, H Koprowski and K Bögel, eds), p 172, Springer-Verlag, Berlin-Heidelberg-New York-Tokyo.
114. Van Steenis G, AL Van Wezel, PJ Van der Marel and CA Hannik. 1981. Dog kidney cell rabies vaccine: some aspects of its control and efficacy in man. In: Cell Culture Rabies Vaccines and Their Protective Effect in Man (Kuwert E, TJ Wiktor and H Koprowski, eds), p 78, International Green Cross, Geneva.
115. Van Wezel AL and G Van Steenis. 1978. Production of an inactivated rabies vaccine in primary dog kidney cells. Dev Biol Stand 40: 69-75.
116. Van Wezel A. 1967. Growth of cell strains and primary cells on microcarriers in homogeneous culture. Nature 216: 64-65.
117. Van Wezel A. 1973. Microcarrier cultures of animal cells. In: Tissue Culture Methods and Application (Kruse P and M Patterson, eds), p 372, Academic Press, New York-London.
118. Van Wezel A. 1977. The large-scale cultivation of diploid cell strains in microcarrier culture. Improvement of microcarriers. Dev Biol Stand 37: 143-147.
119. Vieuchange I, R Bequignon, J Guest and C Vialat. 1956. Bull Acad Nat Med (Paris) 140: 77.
120. Vincent-Falquet JC, L Peyron, M Souvras, JC Moulin, J Tektoff and J Patet. 1989. Qualification of working cell banks for the Vero cell line to produce licensed human vaccines. Dev Biol Stand 70: 153-156.
121. WHO Expert Committee on Rabies, 6th Report. 1973. World Health Organisation Technical Report Series No. 523, Geneva.
122. Wasi C, P Chaiprasithikul, P Puthavathana, L Chavanich and P Thongcharoen. 1985. Immunogenicity and reactogenicity of the new tissue culture rabies vaccine for human use (purified chick embryo cell culture). In: Improvements in Rabies Postexposure Treatment (Vodopija I, KG Nicholson, S Smerdel and U Bijok, eds), p 85, Zagreb Institute of Public Health.
123. Wegmann A, R Gluck, H Keller and JM Matthieu. 1985. A highly efficient, highly purified duck embryo rabies vaccine. Schweiz Med Wochenschr 115: 1779-1781.
124. Wiktor TJ and HF Clarck. 1975. Growth of rabies virus in cell cultures. In: The Natural History of Rabies, p 115, Baer G Med, Academic Press, New York-San Francisco-London.
125. Wiktor TJ, F Sokol, E Kuwert and H Koprowski. 1969. Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc Soc Exp Biol Med 131: 799-805.
126. Wiktor TJ, M Fernades and H Koprowski. 1984. Cultivation of rabies virus in human diploid cells strain WI-38. J Immunol 1984; 93: 353-366.
127. Wiktor TJ, S Plotkin and H Koprowski. 1978. Development and clinical trials of the new human rabies vaccine of tissue culture (human diploid cell) origin. Dev Biol Stand 40: 3-9.
128. Winkler W. 1985. Current status of use of human diploid cell strain rabies vaccine in the US. In: Improvements in Rabies Postexposure Treatment (Vodopija I, KG Nicholson, S Smerdel and U Bijok, eds), p 3, Zagreb Institute of Public Health.